Company: MLTX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001821586-25-000018
Chunk: 108

Company: MoonLake Immunotherapeutics
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 108
---
30, 2025(Unaudited)

Weighted average assumptions for the awards issued during the six months ended June 30, 2025Estimated fair value of the option on the grant date using Black-Scholes model ($)28.36Exercise price ($)41.33Expected term of the award on the grant date (years) (1)6Expected volatility of the share price (2)75%Risk-free interest rate (3)4.4%Expected dividend rate—%(1) The expected term represents the period that share-based awards are expected to be outstanding.(2) The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company’s industry.(3) The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.Weighted average assumptions for the awards issued during the six months ended June 30, 2024Estimated fair value of the option on the grant date using Black-Scholes model ($)31.66Exercise price ($)45.91Expected term of the award on the grant date (years) (1)6Expected volatility of the share price (2)75%Risk-free interest rate (3)4.6%Expected dividend rate—%(1) The expected term represents the period that share-based awards are expected to be outstanding.(2) The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company’s industry.(3) The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.Equity Incentive Plan (Restricted Stock Awards)Number of SharesWeighted-Average Grant Date Fair ValueAwards unvested as of January 1, 2025—$—Awards granted for the six months ended June 30, 2025191,52641.77Awards unvested as of June 30, 2025191,526$41.77Weighted average assumptions for the awards issued during the six months ended June 30, 2025Estimated fair value of Common Shares on the grant date (USD)41.77As of June 30, 2025, the Company had $7.3 million of total unrecognized compensation expense related to restricted stock awards under the Equity Incentive Plan that will be recognized over the weighted average period of 3.67 years.

Note 15 —